Abstract
Patients with a tendency to thrombosis are defined as having thrombophilia. The term “inherited thrombophilia” should be used for individuals with predisposing genetic defects. Hypercoagulability and thrombophilia are synonymous. Thrombophilia is usually suspected in patients with one or more of the following clinical features: idiopathic thrombosis, thrombosis at a young age, recurrent thrombosis, and thrombosis at an unusual site. Individuals who have laboratory abnormalities or clinical disorders that are known to predispose to thrombosis, but have not had an episode of thrombosis, are potentially thrombophilic. Prior to 1993, the diagnosis of a hereditary disorder could be established in only 10– 15% of younger patients presenting with venous thromboembolism (VTE). The only disorders known at this time were deficiencies of antithrombin (AT), protein C, and protein S. With the discovery of the factor V Leiden mutation (activated protein C [APC] resistance; see “Inherited Hypercoagulable States”) and, more recently, the prothrombin gene mutation, it is currently possible to define genetic risk factors in many younger patients with idiopathic venous thrombosis.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc NatlAcad Sci USA 1993;90(3):1004–1008.
Ryan DH, Crowther MA, Ginsberg JS, Francis CW. Relation of factor V Leiden genotype to risk for acute deep venous thrombosis after joint replacement surgery. Ann Intern Med 1998;128(4):270–276.
Kraaijenhagen RA, Anker PS, Koopman MMW, et al. High plasma concentrations of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000;83:5–9.
Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523–526.
Ridker PM, Goldhaber SZ, Danielson E, et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425–1434.
Suggested Reading
Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:204S–233S.
Bates SM, Ginsberg JS. Treatment of deep-vein thrombosis. N Engl J Med 2004;351:268–277.
Bauer KA. Management of thrombophilia. J Thromb Haemost 2003; 1(7):1429–1434.
Büller HM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2004;401S–428S.
Crowther MA, Weitz JI. Ximelagatran: the first oral direct thrombin inhibitor. Expert Opin Investig Drugs 2004;13:403–413.
Den Heijer M, Rosendaal FR, Blom HJ, Gerrits WBJ, Bos GMJ. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb Haemost 1998;80:874–877.
Goldhaber SZ. Thrombolysis in pulmonary embolism: a debatable indication. Thromb Haemost 2001;86:444–451.
Hillarp A, Zöller B, Svensson P, Dahlbäck B. The 20210 A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep vein thrombosis. Thromb Haemost 1997;78:990–992.
Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 2004;126:188S–203S.
Iorio A, Guercini F, Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 2003;1:1906–1913.
Levine JS, BranchD W, Rauch J. The antiphospholipid syndrome. N EnglJ Med 2002;346:752–763.
Simoni P, Prandoni P, Lensing AWA, et al. The risk of recurrent venous thromboembolism in patients with an Arg506-Gln mutation in the gene for factor V (factor V Leiden) N Engl J Med 1997;336:399–403.
Turpie AGG, Norris TM. Thromboprophylaxis in medical patients. The role of low-molecular-weight heparin. Thromb Haemost 2004;92:3–12.
Wells PS, Forster AJ. Thrombolysis in deep vein thrombosis. Is there still an indication? Thromb Haemost 2001;86:499–508.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Hiller, E. (2007). Thrombophilia, Thromboembolic Disease, and Antithrombotic Therapy. In: Munker, R., Hiller, E., Glass, J., Paquette, R. (eds) Modern Hematology. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-149-9_21
Download citation
DOI: https://doi.org/10.1007/978-1-59745-149-9_21
Publisher Name: Humana Press
Print ISBN: 978-1-58829-557-6
Online ISBN: 978-1-59745-149-9
eBook Packages: MedicineMedicine (R0)